Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10241 plus almonertinib versus platinum doublet chemotherapy in EGFR-TKI-failed MET-amplified advanced non-small cell lung cancer
CTR20233789Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dalmelitinib, almonertinib in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Nov 2023; status: completed.
02
Drugs
dalmelitinibalmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20233789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233789.